Beacon Pointe Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Beacon Pointe Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$519K	Buy	+966	New	+$495K	﹤0.01%	1325

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Beacon Pointe Advisors's MDGL Position: Q2 2026 in Review

Beacon Pointe Advisors opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 966 shares worth $519K. The stake represents ﹤0.01% of the portfolio and ranks #1325 among its holdings.

413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Beacon Pointe Advisors held 966 shares of Madrigal Pharmaceuticals worth $519K as of Q2 2026.
Madrigal Pharmaceuticals was a new Beacon Pointe Advisors position in Q2 2026.
Madrigal Pharmaceuticals made up ﹤0.01% of Beacon Pointe Advisors's portfolio in Q2 2026, its #1325 holding.
413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Beacon Pointe Advisors's 13F filing for Q2 2026, filed 18 Aug 2026.